Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 339

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Lamivudine Treatment Can Overcome Cytotoxic T–Cell Hyporesponsiveness in Chronic Hepatitis B: New Perspectives for Immune Therapy

Open access
Boni, Carolina, Penna, Amalia, Ogg, Graham S., Bertoletti, Antonio, Pilli, Massimo, Cavallo, Cristina, Cavalli, Albertina, Urbani, Simona, Boehme, Richard, Panebianco, Ruggero, Fiaccadori, Franco, Ferrari, Carlo·2001·Hepatology
DOI 10.1053/jhep.2001.23045
Open this paper in CoChat — free account

Abstract

The hepatitis B virus (HBV) cytotoxic T lymphocyte (CTL) response in patients with chronic HBV infection is generally weak or totally undetectable. This inability to mount protective CTL responses is believed to be a crucial determinant of viral persistence, and its correction represents an important objective of immune therapies for chronic hepatitis B. However, amplification of CTL responses in vivo may be ineffective if HBV–specific CD8 cells are either absent or nonresponsive to exogenous stimulation. In this study, we asked whether antiviral treatments able to inhibit viral replication and to reduce viral and antigen load can successfully reconstitute CTL responses creating the appropriate conditions for their therapeutic stimulation. For this purpose, the HBV–specific CTL response before and during lamivudine therapy was studied longitudinally in 6 HLA–A2-positive patients with HBeAg+ chronic hepatitis B. Both HBV–specific cytotoxic T cell activity measured by chromium release assay on peptide stimulation in vitro and CD8+ T cell frequency measured ex vivo by HLA–A2/peptide tetramer staining were significantly augmented by lamivudine therapy. This enhancement followed the reconstitution of CD4 reactivity and the decline of viral load induced by therapy. Our study shows that lamivudine treatment in chronic hepatitis B can restore CTL reactivity, making CTL susceptible to exogenous stimulation. This effect may enhance the probability that T cell–based immune therapies delivered after lamivudine treatment can successfully reconstitute a protective CTL response able to cure chronic HBV infection. (Hepatology 2001;33:963–971.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/jhep.2001.23045

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 339

Metadata

Authors
Boni, C., Penna, A., Ogg, G. S., Bertoletti, A., Pilli, M., Cavallo, C., Cavalli, A., Urbani, S., Boehme, R., Panebianco, R., Fiaccadori, F., & Ferrari, C.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2001-04
Volume
33
Issue
4
Pages
963-971
ISSN
0270-9139 (ISSN-L)
DOI
10.1053/jhep.2001.23045
OpenAlex
W2115150071
Cited by
339
References
20
FWCI
23.29
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lamivudine Treatment Can Overcome Cytotoxic T–Cell Hyporesponsiveness in Chronic Hepatitis B: New Perspectives for Immune Therapy. https://app.cochat.ai/papers/10.1053/jhep.2001.23045
The paper
Boni, C., Penna, A., Ogg, G. S., Bertoletti, A., Pilli, M., Cavallo, C., Cavalli, A., Urbani, S., Boehme, R., Panebianco, R., Fiaccadori, F., & Ferrari, C. (2001). Lamivudine Treatment Can Overcome Cytotoxic T–Cell Hyporesponsiveness in Chronic Hepatitis B: New Perspectives for Immune Therapy. Hepatology. https://doi.org/10.1053/jhep.2001.23045

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.